ClearPoint Neuro (CLPT) Stock Price, News & Analysis

Company Overview

ClearPoint Neuro, Inc. is a medical device company specializing in the development and commercialization of real-time magnetic resonance imaging (MRI)-guided technologies for neurosurgical procedures. The company’s core offering, the ClearPoint® Neuro Navigation and Delivery System, enables neurosurgeons to perform minimally invasive procedures with high precision by integrating live MRI feedback during therapy delivery. This platform supports a range of intracranial interventions, including deep brain stimulation lead placement, laser ablation, and targeted drug delivery, with the goal of improving surgical accuracy and patient outcomes.

In addition to its flagship navigation system, ClearPoint Neuro offers SmartFlow™ infusion catheters designed for controlled and uniform distribution of therapeutic agents into brain tissue. These catheters address challenges associated with conventional infusion techniques by reducing reflux and ensuring consistent drug delivery. Together, the navigation system and infusion technology form an integrated approach to treating neurological disorders such as movement disorders, tumors, and epilepsy.

Headquartered in Redwood City, California, ClearPoint Neuro markets its products primarily in the United States and has begun expanding into select European and Asian markets. The company collaborates with leading academic medical centers and research institutions to advance the clinical use of MRI-guided procedures. Through partnerships with neurosurgeons and neurologists, ClearPoint Neuro continues to refine its platform and explore new indications, including gene and cell therapies for central nervous system diseases.

Since its founding, ClearPoint Neuro has been led by a management team with deep expertise in medical device development, radiology and neurosurgery. Guided by a board that includes experienced clinicians and industry veterans, the company remains focused on innovation, regulatory excellence and building a comprehensive portfolio of image-guided solutions. ClearPoint Neuro’s mission is to enable safer, more effective brain therapies and to support the next generation of neurological treatments worldwide.

Key Stats

• Today's Range: $11.25 to $11.97
• 50-Day Range: $11.17 to $14.67
• 52-Week Range: $5.39 to $19.22
• Volume: 462,699 shs
• Average Volume: 256,960 shs
• Market Capitalization: $330.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Buy

ClearPoint Neuro Stock Analysis - MarketRank™

ClearPoint Neuro scored higher than 30% of companies evaluated by MarketBeat, and ranked 757th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

ClearPoint Neuro has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ClearPoint Neuro has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ClearPoint Neuro are expected to grow in the coming year, from ($0.66) to ($0.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ClearPoint Neuro is -15.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ClearPoint Neuro is -15.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ClearPoint Neuro has a P/B Ratio of 12.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.57% of the float of ClearPoint Neuro has been sold short.

Short Interest Ratio / Days to Cover

ClearPoint Neuro has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in ClearPoint Neuro has recently increased by 10.19%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ClearPoint Neuro does not currently pay a dividend.

Dividend Growth

ClearPoint Neuro does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.57% of the float of ClearPoint Neuro has been sold short.

Short Interest Ratio / Days to Cover

ClearPoint Neuro has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in ClearPoint Neuro has recently increased by 10.19%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for CLPT on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ClearPoint Neuro insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $415,173.00 in company stock.

Percentage Held by Insiders

Only 6.11% of the stock of ClearPoint Neuro is held by insiders.

Percentage Held by Institutions

Only 30.08% of the stock of ClearPoint Neuro is held by institutions.

CLPT Stock Analysis - Frequently Asked Questions

How have CLPT shares performed this year?

ClearPoint Neuro's stock was trading at $15.38 at the beginning of 2025. Since then, CLPT stock has decreased by 23.3% and is now trading at $11.80.

How were ClearPoint Neuro's earnings last quarter?

ClearPoint Neuro, Inc. (NASDAQ:CLPT) released its earnings results on Tuesday, May, 13th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.07. The company had revenue of $8.49 million for the quarter, compared to analysts' expectations of $8.21 million. ClearPoint Neuro had a negative trailing twelve-month return on equity of 78.09% and a negative net margin of 64.51%.
Read the conference call transcript.

How do I buy shares of ClearPoint Neuro?

Shares of CLPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ClearPoint Neuro own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ClearPoint Neuro investors own include Arista Networks (ANET), NVIDIA (NVDA), CrowdStrike (CRWD), Axon Enterprise (AXON), Advanced Micro Devices (AMD), Cadence Design Systems (CDNS) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/07/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CLPT
• CIK: 1285550
• Web: www.clearpointneuro.com
• Phone: (949) 900-6833
• Fax: 949-900-6834
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $25.00
• High Stock Price Target: $30.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +112.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.91 million
• Net Margins: -64.51%
• Pretax Margin: -64.50%
• Return on Equity: -78.09%
• Return on Assets: -51.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.53
• Quick Ratio: 2.57

Sales & Book Value

• Annual Sales: $31.39 million
• Price / Sales: 10.51
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.92 per share
• Price / Book: 12.81

Miscellaneous

• Outstanding Shares: 27,990,000
• Free Float: 26,279,000
• Market Cap: $329.86 million
• Optionable: Optionable
• Beta: 0.92